Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial

被引:1
|
作者
Lankarani, Kamran Bagheri [1 ]
Safa, Hoda [2 ,4 ]
Ghahramani, Sulmaz [1 ]
Sayari, Mohammad [1 ]
Malekhosseini, Seyed-Ali [3 ]
机构
[1] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Dept Gastroenterol, Shiraz, Iran
[3] Shiraz Univ Sci, Shiraz Transplant Res Ctr, Shiraz, Iran
[4] Hormozgan Univ Med Sci, Dept Gastroenterol, Bandar Abbas, Iran
关键词
Acute kidney injury; Early allograft dysfunction; Length of hospital stay; Nosocomial infection; Somatostatin analog; EARLY ALLOGRAFT DYSFUNCTION; ISCHEMIA-REPERFUSION INJURY; RENAL-FUNCTION; HYPERTENSION; DEFINITION; VALIDATION; BAICALIN;
D O I
10.6002/ect.2022.0080
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant. Octreotide, through its various mechanisms, may have a role in preventing these complications.Materials and Methods: In this randomized, double-blind placebo-controlled clinical trial, we randomly assigned 50 patients who underwent deceased donor liver transplant and fulfilled the study inclusion requirements to receive either octreotide infusion for 3 days in the first 3 days after transplant in the intensive care unit or placebo. The eligible patients were properly informed while on the transplant wait list and gave their consent to participate in the study. The rates of acute kidney injury within the first 7 days after transplant (based on KDIGO criteria), early allograft dysfunction, and nosocomial infection; total length of hospital stays and intensive care unit admissions; and intubation time were recorded and compared between the 2 groups.Results: No significant differences were found between the 2 groups with regard to demographic charac-teristics and graft factors (P > .05). However, acute kidney injury, early allograft dysfunction, and nosocomial infection rates were significantly lower in the octreotide group compared with the control group (P < .05). Moreover, a significant difference was observed between the 2 groups with regard to length of hospital stay and intensive care unit admissions (P < .05). For infection, female patients had a higher likelihood of infection than male patients (odds ratio = 23.19). Intensive care unit admission was associated with a higher probability of early graft dysfunction (odds ratio = 1.34). In contrast, longer intubation time was associated with a decrease in the probability of early graft dysfunction (odds ratio = 0.93).Conclusions: This study showed that octreotide infusion in the first 3 days after liver transplant could improve renal and allograft function and reduce infection and length of hospital stay.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 50 条
  • [41] The cult of the double-blind placebo-controlled trial
    Ellis, SJ
    Adams, RF
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1997, 51 (01): : 36 - 39
  • [42] A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
    Richard, I. H.
    McDermott, M. P.
    Kurlan, R.
    Lyness, J. M.
    Como, P. G.
    Pearson, N.
    Factor, S. A.
    Juncos, J.
    Ramos, C. Serrano
    Brodsky, M.
    Manning, C.
    Marsh, L.
    Shulman, L.
    Fernandez, H. H.
    Black, K. J.
    Panisset, M.
    Christine, C. W.
    Jiang, W.
    Singer, C.
    Horn, S.
    Pfeiffer, R.
    Rottenberg, D.
    Slevin, J.
    Elmer, L.
    Press, D.
    Hyson, H. C.
    McDonald, W.
    NEUROLOGY, 2012, 78 (16) : 1229 - 1236
  • [43] Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial
    Riche, Daniel M.
    Riche, Krista D.
    Blackshear, Chad T.
    McEwen, Corey L.
    Sherman, Justin J.
    Wofford, Marion R.
    Griswold, Michael E.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014
  • [44] FISH OIL IN PSORIASIS - A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
    BITTINER, SB
    TUCKER, WFG
    BLEEHEN, SS
    BRITISH JOURNAL OF DERMATOLOGY, 1987, 117 : 25 - 26
  • [45] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF FISH OIL IN PSORIASIS
    BITTINER, SB
    TUCKER, WFG
    CARTWRIGHT, I
    BLEEHEN, SS
    LANCET, 1988, 1 (8582): : 378 - 380
  • [46] A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis
    Knobler, RM
    French, LE
    Kim, Y
    Bisaccia, E
    Graninger, W
    Nahavandi, H
    Strobl, FJ
    Keystone, E
    Mehlmauer, M
    Rook, AH
    Braverman, I
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (05) : 793 - 799
  • [47] Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism
    Kahaly, George J.
    Riedl, Michaela
    Koenig, Jochem
    Diana, Tanja
    Schomburg, Lutz
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2017, 102 (11): : 4333 - 4341
  • [48] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NIMODIPINE IN ACUTE STROKE
    MURPHY, JJ
    LANCET, 1990, 336 (8725): : 1205 - 1209
  • [49] A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression
    E Sherwood Brown
    John Park
    Christine E Marx
    Linda S Hynan
    Claire Gardner
    Domingo Davila
    Alyson Nakamura
    Prabha Sunderajan
    Alexander Lo
    Traci Holmes
    Neuropsychopharmacology, 2014, 39 : 2867 - 2873
  • [50] A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression
    Hantsoo, Liisa
    Ward-O'Brien, Deborah
    Czarkowski, Kathryn A.
    Gueorguieva, Ralitza
    Price, Lawrence H.
    Epperson, C. Neill
    PSYCHOPHARMACOLOGY, 2014, 231 (05) : 939 - 948